2023-505034-10-00已完成2 期
AN OPEN-LABEL, MULTICENTER, GLOBAL PHASE II BASKET STUDY OF ENTRECTINIB FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS THAT HARBOR NTRK1/2/3, ROS1, OR ALK GENE REARRANGEMENTS
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 131
- 试验地点
- 34
- 主要终点
- Objective Response Rate (ORR), defined as the proportion of patients with complete response (CR) or partial response (PR)
研究概览
简要总结
To determine the objective response rate of entrectinib, as assessed by BICR, in each patient population basket of solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene rearrangement
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed diagnosis of locally advanced or metastatic solid tumor that harbors an NTRK1/2/3, ROS1, or ALK gene rearrangement that is predicted to translate into a fusion protein with a functional TrkA/B/C, ROS1, or ALK kinase domain, respectively, without a concomitant second oncodriver (e.g., EGFR, KRAS), as determined by Foundation Medicine, Inc. or by any nucleic acid-based diagnostic testing method (please refer to Section 5.1) performed at a local CLIA-certified or equivalently-accredited diagnostic laboratory. These are patients for whom no alternative effective standard therapy is available or for whom standard therapy is considered unsuitable or intolerable. Note: Patients diagnosed with anaplastic large cell lymphoma (ALCL) harboring a gene rearrangement of interest are no longer eligible.
- •Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 and minimum life expectancy of at least 4 weeks.
- •Adequate liver function as defined by the following criteria: -Serum aspartate transaminase (AST; serum glutamic oxaloacetic transaminase (SGOT)) and serum alanine transaminase (ALT; serum glutamic pyruvic transaminase (SGPT)) ≤ 3.0 × upper limit of normal (ULN); ≤ 5.0 × ULN if liver metastases are present -Total serum bilirubin ≤ 2.0 × ULN; patients with a known history of Gilbert's syndrome and/or isolated elevations of indirect bilirubin are eligible
- •Women patients of childbearing potential: • Must have a negative serum pregnancy test during screening and must not be breastfeeding or intending to become pregnant during the study • Must agree to remain abstinent or use single or combined contraception methods that result in a failure rate of < 1% per year prior to entering into the study and for 5 weeks following the last dose of study drug • Allowance for locally recognized adequate methods of contraception • Must agree to refrain from donating eggs during the same period -Oral contraceptives and intrauterine hormone releasing systems (IUSs) used by female patients must be combined with a barrier method. Male patients with female partners of childbearing potential: • Must agree to use highly effective contraception during the study and for 3 months following the last dose of study drug. • Requirement for male patients to abstain from donating sperm during the study and for 3 months after study.
- •Ability to swallow entrectinib intact without chewing, crushing, or opening the capsules. Please refer to the Section 5.2.2 of the Protocol for the complete list of the Inclusion criteria
- •For patients enrolled via local molecular testing, an archival or fresh tumor tissue (unless medically contraindicated) is required to be submitted for independent central molecular testing at Foundation Medicine, Inc.
- •or to the alternative, approved central laboratory for that region.
- •Measurable disease as assessed locally using RECIST v1.
- •Note: Patients with non-measurable disease (evaluable disease only) will be eligible for enrollment in the "non-evaluable for the primary endpoint" basket and will mainly contribute to assessment of safety, PK, and other secondary endpoints.
- •Patients with CNS involvement, including leptomeningeal carcinomatosis, which is either asymptomatic or previouslytreated and controlled, are allowed. The use of seizure prophylaxis is allowed as long as patients are taking non-enzyme-inducing anti-epileptic drugs (non-EIAEDs).
- •Prior anticancer therapy is allowed (excluding approved or investigational Trk, ROS1, or ALK (non-NSCLC patients only) inhibitors in patients who have tumors that harbor those respective gene rearrangements). Note: The ALK basket is closed to enrolment.
- •At least 2 weeks or 5 half-lives, whichever is shorter, must have elapsed after prior chemotherapy or small molecule targeted therapy, respectively, at the time of the start of entrectinib treatment. Note: For targeted therapies, there must be no signs of disease flare or accelerated disease progression after treatment discontinuation.
- •At least 4 weeks must have elapsed since completion of antibody-directed therapy at the time of the start of Entrectinib treatment.
- •Prior radiotherapy is allowed if more than 14 days have elapsed since the end of treatment. Patients who received brain irradiation must have completed whole brain radiotherapy at least 14 days prior and/or stereotactic radiosurgery at least 7 days prior to the start of entrectinib treatment.
- •Age ≥ 18 years
排除标准
- •Current participation in another therapeutic clinical trial.
- •Peripheral sensory neuropathy Grade ≥
- •Known active infections that would interfere with the assessment of safety or efficacy of entrectinib (bacterial, fungal, or viral) with the exceptions of human Immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) infections, as noted below: – HIV positivity, only if patients meet any of the following criteria: Patients with a CD4+ T-cell count of <350 cells/μL Patients with a detectable HIV viral load Patients with a history of an opportunistic infection within the past 12 months Patients who are on stable antiretroviral therapy for < 4 weeks – Active HBV infection (chronic or acute; defined as having a positive hepatitis B surface antigen [HBsAg] test), with the following exception: Patients with past HBV infection or resolved HBV infection (defined as the presence of hepatitis B core antibody [HBcAb] and absence of HBsAg) if they are negative for HBV DNA – HCV antibody (HCV Ab) positivity, with the following exceptions: Patients who are HCV Ab-positive but HCV RNA-negative due to prior treatment or natural resolution are eligible Patients with untreated HCV if the HCV is stable, the patient is not at risk for hepatic decompensation, and the intended treatment is not expected to exacerbate the HCV infection Patients on concurrent HCV treatment if they have HCV below the limit of quantification
- •Active gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would reasonably impact drug absorption.
- •Known interstitial lung disease, interstitial fibrosis, or history of tyrosine kinase inhibitor-induced pneumonitis. Note: Radiation-induced lung disorders are not included in this exclusion criterion.
- •Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for entry into this study or could compromise protocol objectives in the opinion of the Investigator and/or the Sponsor
- •Prior treatment with approved or investigational Trk, ROS1, or ALK inhibitors in patients who have tumors that harbor those respective gene rearrangements. Note: In cases where the patient was intolerant to prior Trk, ROS1, or ALK inhibitors, please discuss with the Sponsor. In addition, prior treatment with crizotinib is permitted ONLY in ALK- or ROS1-rearranged NSCLC patients presenting with CNS-only progression. Other ALK or ROS1 inhibitors are prohibited in that scenario.
- •History of other previous cancer that would interfere with the determination of safety or efficacy of entrectinib with respect to the qualifying solid tumor malignancy. Note: Patients presenting with dual primary cancers may enroll in the "non-evaluable for the primary endpoint" basket if at least one of the cancers harbor an NTRK1/2/3, ROS1, or ALK gene rearrangement as per Inclusion Criterion
- •Familial or personal history of congenital bone disorders or bone metabolism alterations
- •Incomplete recovery from any surgery prior to the start of entrectinib treatment that would interfere with the determination of safety or efficacy of entrectinib.
- •Any condition (in the past 3 months) that would interfere with the determination of safety or efficacy of entrectinib: myocardial infarction, unstable angina, coronary/peripheral artery bypass graft, cerebrovascular accident or transient ischemic attack, stroke, symptomatic bradycardia, or uncontrolled arrhythmias requiring medication.
- •History of recent (within the past 3 months) symptomatic congestive heart failure or ejection fraction 50% observed during screening for the study
- •History of non-pharmacologically induced prolonged QTc interval (e.g., repeated demonstration of a QTc interval > 450 milliseconds from ECGs performed at least 24 hours apart).
- •History of additional risk factors for torsades de pointes (e.g., family history of long QT syndrome).
研究组 & 干预措施
Rozlytrek 200 mg hard capsules
Test
干预措施: Rozlytrek 200 mg hard capsules (Drug)
结局指标
主要结局
Objective Response Rate (ORR), defined as the proportion of patients with complete response (CR) or partial response (PR)
Objective Response Rate (ORR), defined as the proportion of patients with complete response (CR) or partial response (PR)
次要结局
- Duration of Response (DOR)
- Time to Response (TTR)
- Clinical Benefit Rate (CBR)
- Intracranial tumor response in patients with measurable brain metastases, as determined by BICR using RANO or RANO-BM as applicable
- CNS Progression-Free Survival (CNS-PFS) in patients with measurable CNS disease,
- Progression-Free Survival (PFS)
- Overall Survival (OS)
- Type, incidence, severity, timing, seriousness, and relatedness of adverse events and laboratory abnormalities
- Population PK
- Ventricular repolarization
- Quality-of-life and health status to examine biological markers of bone formation and resorption and markers of calcium metabolism
- Assessment of bone mineral density (BMD) via dual X-ray absorptiometry (DXA) scans
研究者
Trial Information Support Line-TISL
Scientific
F. Hoffmann-La Roche AG
研究点 (34)
Loading locations...
相似试验
招募中
2 期
A study to learn more about how well treatment with sevabertinib (BAY2927088) tablets works and how safe it is in participants who have a solid tumor with mutations of the human epidermal growth factor receptor 2 (HER2)2024-517419-62-00Bayer Consumer Care AG, Bayer AG37
招募中
2 期
Taletrectinib in ROS1 Positive Lung Cancer Phase 2 Global StudyNon-small Cell Lung Cancer2024-516604-41-00Anheart Therapeutics Inc.98
招募中
3 期
A Worldwide Study Testing the New Drug Olverembatinib for Patients with Chronic Phase Chronic Myeloid Leukemia (POLARIS-2)2024-511495-32-00Ascentage Pharma Group Inc., Ascentage Pharma Group Inc.138
招募中
2 期
A phase II trial of MK-3475 (pembrolizumab) in children and young adults with classical Hodgkin lymphoma2023-504821-38-00Merck Sharp & Dohme LLC195
招募中
3 期
52 weeks double-blind, double-dummy, randomized placebo-controlled trial to evaluate safety, efficacy and tolerability of remibrutinib in comparison to placebo with omalizumab as active control in adult patients with CSU and inadequate response to H1-antihistamine and an open-label 52-week optional extension to assess long-term efficacy, safety and tolerability of remibrutinib 25 mg b.i.d.2022-502161-19-00Novartis Pharma AG214